Screening for Ovarian Malignancy

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 1, 2023

Study Completion Date

January 1, 2023

Conditions
Early Detection of Ovarian Cancer
Interventions
DIAGNOSTIC_TEST

Assesment of Different NEoplasias in the adenexa model

The ADNEX model includes nine parameters; Age, CA-125 level, Oncology center (yes/no), and 6 ultrasound features which are maximal diameter of the lesion, maximal diameter of the largest solid part, more than 10 locules (yes/no), number of papillary projections (0/1/2/3/more than 3), acoustic shadow, and ascites

DIAGNOSTIC_TEST

Risk of malignancy index

The RMI was measured as follows; Menopausal status (score is 3 as all patients were postmenopausal X Ultrasound score is based on assessment of 5 features and with the presence of one feature, the score is 1 while if more than one feature is present, the score is 3; the five ultrasound features are the presence of solid components, multilocularity, bilaterality, ascites, and metastases X CA - 125 level

DIAGNOSTIC_TEST

Histopathologic examination

Histopathologic examination of all excised specimens was done as this is the gold standard test for detecting ovarian malignancy

Trial Locations (1)

Unknown

AinShams university maternity hospital, Cairo

All Listed Sponsors
lead

Ain Shams Maternity Hospital

OTHER

NCT06348784 - Screening for Ovarian Malignancy | Biotech Hunter | Biotech Hunter